TRAX
First Tracks Biotherapeutics Inc
NASDAQ · Healthcare · Biotechnology · US
$40.46
−4.82%Income statement
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | — | — | — |
| Cost of Revenue | 139.6M | 152.3M | — |
| Gross Profit | (139.6M) | (152.3M) | — |
| Operating Expenses | |||
| R&D Expense | 139.6M | 152.3M | 97.6M |
| SG&A Expense | 39.4M | 28.8M | 20.9M |
| General & Admin Expense | 39.4M | 28.8M | 20.9M |
| Selling & Marketing Expense | — | — | — |
| Other Expenses | (139.6M) | (152.3M) | — |
| Total Operating Expenses | 39.4M | 28.8M | 118.5M |
| Cost and Expenses | 179.0M | 181.1M | 118.5M |
| Operating Income (EBIT) | (179.0M) | (181.1M) | (118.5M) |
| Non-Operating | |||
| Interest Income | 12.9M | 17.4M | 12.3M |
| Interest Expense | — | — | — |
| Net Interest Income | 12.9M | 17.4M | 12.3M |
| Other Non-Op Income/Expense | 12.9M | 17.4M | 12.3M |
| Non-Operating Income (excl Interest) | — | — | — |
| EBT (Pre-Tax Income) | (166.1M) | (163.7M) | (106.2M) |
| Income Tax Expense | — | — | — |
| Bottom Line | |||
| Net Income | (166.1M) | (163.7M) | (106.2M) |
| Earnings from Cont. Ops | (166.1M) | (163.7M) | (106.2M) |
| Earnings from Discont. Ops | — | — | — |
| Bottom Line Net Income | (166.1M) | (163.7M) | (106.2M) |
| Per Share | |||
| Basic EPS | $0.00 | $0.00 | ($3.05) |
| Diluted EPS | $0.00 | $0.00 | ($3.05) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 |
| Shares | |||
| Basic Shares Outstanding | 34.7M | 34.7M | 34.7M |
| Diluted Shares Outstanding | 34.7M | 34.7M | 34.7M |
| Profitability Metrics | |||
| EBITDA | (178.4M) | (178.7M) | (116.1M) |
| D&A | 559.0K | 2.4M | 2.4M |
| EBIT | (179.0M) | (181.1M) | (118.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026